# Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer

> **NCT02209441** · — · AVAILABLE · sponsor: **Chinese Academy of Medical Sciences**

## Conditions studied

- Gastric Cancer.

## Interventions

- **DRUG:** Phase I Dose-finding Study of Sorafenib Study

## Key facts

- **NCT ID:** NCT02209441
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02209441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02209441, "Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02209441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*